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Purpose: Smooth muscle cell (SMC) migration and proliferation are prominent features of 
intimal hyperplasia. Previous tudies have shown that inhibition of c- myb inhibits arterial 
SMC proliferation. Our goal was to evaluate the effect of an antisense oligonucleotide 
targeted to c-myb on the proliferation and migration of SMC explanted from synthetic 
vascular grafts. 
Methods: SMCs were enzymatically removed from aortas and Dacron grafts explanted from 
dogs (n = 5). For proliferation studies, quiescent SMCs were incubated with either 0.0, 
0.5, 5.0, or 10.0 ~tM antisense (GTGTCGGGGTCTCCGGGC) or sense (GCCCG- 
GAGACCCCGACAC) ollgonucleotides to c-myb. Proliferation was measured after 24 
hours by incorporation of [3H]thymidine. Migration was assessed 24 hours after a razor 
injury. 
Results: Antisense to c-myb consistently inhibited proliferation and migration of both 
native aortic and graft SMCs in a dose-dependent fashion. At a concentration of 10 ~tM 
antisense oligonucleotide, aortic and graft SMC proliferation rates were 32% + 20% and 
56% + 9% of control samples, respectively. At 25 ~tM antisense, the number of migrating 
aortic and graft SMCs decreased to41.9% + 26.8% and 51.9% + 34.1% of control samples, 
respectively. 
Conclusions: Our results uggest that antisense oligonucleotides to c-myb may be useful in 
the inhibition of SMC proliferation and migration associated with development of intimal 
hyperplasia. (J Vasc Surg 1996;23:783-91.) 
Intimal hyperplasia ( IH) is characterized by 
smooth muscle cell (SMC) accumulation and matrix 
deposition, which is most severe adjacent o the 
anastomoses of prosthetic grafts. 1'2 Vascular SMCs 
normally exist in a quiescent, contractile state, but 
after injury, such as implantation of a vascular graft, 
SMCs enter a synthetic state. They migrate onto the 
vascular graft, proliferate, and produce abundant 
extracellular matrix material. Both SMC migration 
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and proliferation contribute to the accumulation of 
SMCs in the anastomotic regions and are important 
early events in the development of IH,  which may 
contribute to the eventual prosthetic vascular graft 
occlusion. 
The cause o f lH  is not clearly understood and the 
signals that stimulate SMC migration and prolifera- 
tion have not been defined completely. After arterial 
injury SMCs are modified to produce and respond to 
a variety of mitogens, including platelet derived 
growth factor (PDGF) and basic fibroblast growth 
factor (bFGF). Normal vascular SMCs do not secrete 
measurable quantities of PDGF, but SMCs from 
mechanically injured rat arteries ecrete PDGF 3 and 
express mRNA for PDGF. 4 In addition, mRNA for 
bFGF and immunoreactive bFGF is found both in the 
cytoplasm of replicating endothelial cells and in SMCs 
after balloon injury, but not in quiescent cells. ~ 
Similarly, in prosthetic grafts mitogen production is 
increased over that of the native artery, which suggests 
that a variety of mitogens timulate SMC migration 
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and proliferation on grafts. 610 Infusion of antibodies 
to PDGF or bFGF reduces intimal thickening after 
arterial injury, which suggests he importance of these 
mitogens in IH. 11-13 These antibodies, targeted at a 
single mitogen, however, are only partially effective in 
inhibiting IH, perhaps because of the multiplicity of 
signals for SMC migration and proliferation. There- 
fore, agents uch as antisense oligonucleotides, which 
block a common pathway shared by multiple mito- 
gens, may be more effective. 
After mitogenic stimulation, c-myb and other 
proto-oncogenes are expressed by SMCs before pro- 
liferation. Studies by Simons et al. 14'1s document 
suppression of SMC proliferation i  vitro and in vivo 
after arterial injury by inhibition of c-myb using an 
antisense oligonucleotidc directed against c-myb (c- 
myb antisense). The current study was undertaken to 
assess the effect hat c-myb antisense has on prolifera- 
tion of graft SMCs compared with arterial SMCs 
because dramatic differences exist in their mitogen 
production.16 Perhaps more importantly, the effect of 
c-myb antisense on migration of graft and arterial 
SMCs was evaluated because SMC migration is an 
important and initiating event in the SMC accumu- 
lation associated with the development of IH. 
MATERIALS AND METHODS 
To obtain graft SMCs, five adult female beagles 
underwent implantation of thoracoabdominal Da- 
cron grafts seeded with autologous jugular vein en- 
dothelial cells. This canine model has been previously 
characterized 16 and provides reliable recovery of SMC 
from graft and artery. The dogs ranged in age from 81 
to 194 weeks and weighed from 8.8 to 12.5 kg. The 
protocol for animal studies was approved by the insti- 
tutional committee on animal use. Care complied 
with the "Principles of Laboratory Animal Care" for- 
mulated by the National Society for Medical Research 
and the Guide for the Care and Use of Laboratory Ani- 
reals (NIH Publication No. 86-23, revised 1985). 
Graft seeding and implantation. For graft im- 
plantation, anesthesia was induced with thiopental 
sodium (20 mg/kg) and maintained with 1%-to-2% 
isoflurane anesthesia. A Cooley double-velour knitted 
Dacron graft (6-mm internal diameter, 22-cm long; 
Meadox Medicals Inc.; Oaldand, N.J.) was seeded 
with autologous endothelial cells that had been har- 
vested enzymatically from the external jugular veins, 
as previously described. 16'17 The graft then was im- 
planted in a thoracoabdominal position with an 
end-to-end proximal anastomosis to the proximal 
descending thoracic aorta and an end-to-side distal 
anastomosis to the infrarenal aorta. 
Graft removal. Twenty weeks after implantation 
the grafts and native aortas were removed for cell 
harvest. The animals were anesthetized asdescribed 
above. Intravenous heparin sodium (150 units/kg) 
and papaverine (90 ng/kg) were administered before 
graft removal. The graft and native vessels were 
carefully isolated from adjacent tissues, flushed with 
1 L of Medium 199 (M199; Sigma; St. Louis), and 
removed for cell harvest. 
Cell harvest and maintenance. SMCs were ob- 
tained from the graft and native aorta after emoval of 
endothelial cells. The luminal surface initially was 
incubated in collagenase A (630 tmits/ml; Boeh- 
ringer Mannheim Biochemicals; Indianapolis) for 
10 minutes, and endothelial cells were removed by 
gently scraping with a rounded spatula twice and 
rinsing with M 199. After the outer capsule of the graft 
was carefully removed, the remaining raft and inner 
capsule was cut into 5x5-mm pieces. The medial layer 
was stripped from the aorta and minced into 5x5-mm 
pieces. To harvest graft and arterial SMCs, minced 
pieces were agitated for 2 hours in 5 ml of M199 
containing 15 units/ml clastase type III (Sigma), 170 
units/ml collagenase A, 2 mg/ml crystalline bovine 
serum albumin (Boehringer Mannheim), and 0.375 
mg/ml soybean trypsin inhibitor (Boehringer Mann- 
heim). The medium containing SMCs then was 
removed and centrifuged at 300g for 5 minutes to 
sediment cells. SMCs were resuspended in M199 with 
20% fetal bovine serum (FBS; HyClone Laboratories; 
Logan, Utah) and plated in tissue culture dishes 
precoated with FBS. Homogeneity of SMC isolates 
was confirmed by immunocytochemistry using anti- 
body to SMC 0~-actin (Sigma). 
SMC proliferation. Confluent primary SMCs 
from the aorta and midportion of the graft were 
passaged and plated in Falcon 12-well tissue culture 
plates (Becton Dicldnson; Lincoln Park, N.J.) at a 
density of 5000 cells/cm 2 in Dulbecco's modified 
Eagle's medium/Ham's F-12 (DMEM/F-12; 
Sigma) containing 10% FBS for 24 hours to allow cell 
attachment. The medium was changed to DMEM/F- 
12 with 0.5% FBS to arrest he cells' growth for 72 
hours. Cells then were stimulated with DMEM/F- 12 
containing 10% FBS, and at the same time either sense 
(GCCCGGAGACCCCGACAC) or antisense (GT- 
GTCGGGGTCTCCGGGC) phosphorothioate oli- 
gonucleotides to c-myb (Promega; Madison, Wis.) 
were added at concentrations of 0.0, 0.5, 5.0, and 
10.0 gM for 24 hours. The cells were incubated with 
0.5 gCi [3H]thymidine during the final 6 hours of 
stimulation, washed twice with 1 ml 5% trichloroace- 
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tic acid (TCA; Sigma), lysed with 0.25 M NaOH, and 
added to 5 ml of liquid scintillation cocktail (Fischer 
Scientific, Pittsburgh) for analysis in a gamma 
counter. All studies on cells from each dog were 
performed in duplicate. The value for SMCs from 
each segment of graft and native artery was obtained 
from the average of two wells. For each dog, the 
control wells with no oligonucleotide were consid- 
ered to represent 100% stimulation with FBS, and 
each experimental sample was calculated as a percent- 
age of the control sample. Data were expressed as the 
mean + SD and were analyzed with Student's t test. 
SMC migration. Migration was assessed with a 
standard razor-injury model, is Confluent first-pas- 
sage SMCs from the aorta and midportion of the graft 
were passaged and plated in Falcon 12-well tissue 
culture plates at a density of 200,000 cells per well in 
DMEM containing 20% FBS and grown to conflu- 
ence. The medium then was changed to DMEM and 
0.5% FBS for 48 hours to arrest he growth of the 
SMCs. A razor blade was pressed gently through the 
cell layer into the plastic well to mark the starting line, 
then swept o one side of the cut, removing the SMCs. 
Cells were washed, and sense or antisense oligonucle- 
otides to c-myb were added at concentrations'of 0.0, 
0.5, 5.0, or 25 gM in DMEM with 0.5% FBS. All 
studies were performed in triplicate. Cells were fixed 
and stained with Mayers modified hematoxylin stain 
(Poly Scientific; Bay Shore, N.Y.) 24 hours after azor 
injury. The cells were imaged by a charge-coupled 
device digital camera (Sony Corp.; Tokyo) mounted 
on a phase-contrast microscope. The image was 
transferred to a Macintosh computer (Apple 
Computer; Cupertino, Calif.) by a Data Translations 
image capture board, and image analysis was per- 
formed with Image 1.50 software from the NIH. The 
number of cells that moved across the injury line and 
the perpendicular distance traveled were measured in
at least wo different randomly selected fields in each 
well. Data were expressed as the mean _+ SD and were 
analyzed with Student's t test. 
SMC viability, Cell viability was evaluated with 
three methods: trypan blue staining (Sigma), fluores- 
cent DNA assay, and protein synthesis assay. Staining 
with trypan blue was performed by rinsing the well 
gently with serum-free medium twice and then ap- 
plying 10 gl oftrypan blue in 1000 gl PBS directly to 
each well for 1 minute. The well was rinsed again and 
visually inspected with phase contrast microscopy. 
Nonviable cells that stained blue and nonstaining 
viable cells were counted in three fields per well. 
Nonviable cell counts were expressed as a percent of 
the total cell count. Testing was performed in trip- 
licate. 
The fluorescent DNA assay was performed as 
described by Labarca and Paigen. 19 Cells were har- 
vested with 0.05% trypsin solution and sonicated. The 
cell lysate (25 ~tl) was diluted with phosphate/NaCl 
buffer (750 gl) and bis-benzimide solution (750 ~tl). 
Relative fluorescence was determined in a fluorimeter 
with excitation set at 356 nm and emission set at 458 
nm. A standard curve was prepared with calf thymus 
DNA. Amounts were estimated by nonlinear regres- 
sion with the logistic equation and expressed as gg of 
DNA per well. 
Both secreted and cell-associated protein synthe- 
sis was determined asanother measure of cell viability. 
Briefly, [3H]leucine (2 gCi/ml; DuPont Diagnostic 
Imaging Div.; N. Billerica, Mass.) was added to tissue 
culture wells for 18 hours. Secreted protein synthesis 
was measured as described by Fox and DiCorleto. 2° 
The conditioned media was collected and centrifuged 
at low speed to remove cellular debris. Proteins in the 
supernatant were precipitated with 5% TCA and 
0.25% tannic acid solution, and the final precipitate 
was solubilized with 0.25 M NaOH. Radioactivity 
was determined in a liquid scintillation counter. 
Results were expressed as the percentage of added 
[3H]leucine incorporated into TCA-precipitable ma- 
terial. In addition, cell-associated protein synthesis 
was determined by lysing cells and precipitating 
protein with a TCA/tannic acid solution. Again the 
precipitate was solubilized with 0.25 M NaOH and 
the radioactivity determined in a liquid scintillation 
counter. Results were expressed as described above. 
RESULTS 
Proliferation studies were performed to deter- 
mine whether growth of aortic and graft SMCs was 
inhibited differentially by c-myb antisense. A dose- 
dependent inhibition of both aortic and graft SMC 
proliferation by c-myb antisense was observed in 
SMCs obtained from three dogs (Fig. 1, A). At a 
concentration of 10 btM antisense oligonucleotides, 
graft SMC proliferation was 56% + 9% of the control 
sample (100%+20%, p < 0.0l), and aortic SMC 
proliferation was 32% + 20% of the control sample 
(100 + 7%, p < 0.01). Graft SMC proliferation was 
suppressed less than aortic SMC proliferation when 
treated with 5 ~tM and 10 btM antisense 
oligonucleotide; however, the differences were not 
statistically significant (p > 0.05). Sense oligonucle- 
otide did not consistently or significantly (p > 0.05) 
reduce proliferation at any concentration (Fig. 1, B). 
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Fig. 1. Effect ofc-myb ant±sense ongraft and aortic SMC proliferation. SMCs were stimulated 
with 10% FBS; [3H]thymidinc incorporation was measured during hours 18 to 24 and compared 
with untreated control samples. A, Graft and aortic SMC proliferation, represented aspercent of 
control samples, after treatment with c-myb ant±sense. B, Graft and aortic SMC proliferation, 
represented aspercent of control samples, after treatment with sense oligonucleotides toc-myb. 
Aortic SMC proliferation was significantly ower in 5 
~tM and 10 ~tM ant±sense than sense oligonucleotide 
(p = 0.01 and p < 0.04, respectively). Graft SMC 
proliferation was consistently lower when treated with 
ant±sense compared with sense oligonucleotide; how- 
ever, the difference did not reach statistical signifi- 
cance at any concentration. 
The ability of SMCs to proliferate after exposure 
to c-myb ant±sense was tested to document hat 
inhibition found in proliferation studies was not a 
result of cell death induced by the addition of oligo- 
nucleotides to the cell culture. Quiescent SMCs were 
incubated with 0, 5, or 10 ~tM ant±sense or sense 
oligonucleotide for 24 hours. The medium was re- 
moved, cells were stimulated with 10% FBS, and 
proliferation was measured by [3H]thymidine incor- 
poration. Proliferation of graft and aortic SMCs was 
not significantly altered by oligonucleotide prcincu- 
bat±on, ranging from 88% to 106% of control wells 
(100% ± 4% for graft SMCs, 100% + 24% for aortic 
SMCs; Fig. 2). This confirmed that cells remained 
viable during a 24-hour incubation in oligonucle- 
otide. 
The effect of ant±sense oligonucleotide on migra- 
tion was also studied on SMCs obtained from two 
dogs. Aortic and graft SMC migration, measured as 
the number of migrating cells, was inhibited in a 
dose-dependent fashion by c-myb ant±sense, but not 
by sense oligonucleotide (Fig. 3). In 25 ~tM ant±sense 
the number of aortic SMCs that migrated ecreased 
to 41.9% _+ 26.8% of control wells (100.0% ± 30.4%, 
p < 0.001), whereas the number of graft SMCs was 
51.9% + 34.1% of control wells (100.0% + 27.6%, 
p < 0.05). Sense oligonucleotide had no significant 
effect on the number of either aortic or graft SMCs 
that migrate, and in all cases the number of migrating 
SMCs was significantly decreased with ant±sense com- 
pared with sense oligonucleotide (p < 0.03). The 
mean distance traveled by SMCs was also reduced 
by c-myb ant±sense (Fig. 4). In 5 ~tM and 25 ~tM 
c-myb ant±sense, the distance aortic SMCs migrated 
was reduced to 86.5%_+10.6% (p=0.04) and 
72.9% ± 20.2% (p < 0.01), respectively, compared 
with control samples (100.0%±21.0%), whereas 
the distance graft SMCs migrated was reduced 
to 82.7_+ 12.7% (p< 0.03) and 78.2%_+8.9% 
(p<0.01),  respectively, compared with control 
samples (100.0% _+ 17.1%). Inhibition of aortic SMC 
migration distance was significantly greater by c-myb 
ant±sense (5 gM and 25 ~tM) than sense oligonucle- 
or±des (p = 0.001 and p = 0.003, respectively); how- 
ever, graft SMC migration distance in ant±sense was 
not significantly inhibited compared with sense. No 
significant difference was found between aortic or 
graft SMCs in either number of cells migrating or 
distance travelled. 
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Fig. 2. Reversibility of inhibitory effects of c- myb antisense on SMC proliferation. Aortic SMCs 
were incubated with either antisense or sense oligonucleotide to c-myb for 24 hours, the 
oligonucleotide r moved, and proliferation measured by [3H]thymidine incorporation 18 to 24 
hours later. 
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Fig. 3. Effect of c- myb antisense on number of migrating SM Cs. Confluent SMCs were injured, 
incubated in varying concentrations of oligonucleotide, and number of migrating cells at 24 
hours quantitated. A, Graft and aortic SMCs migrating in presence of c-myb antisense, 
represented aspercent of control sample (control = 159 aortic SMCs or 124 graft SMCs per 
field). B, Graft and aortic SMC migrating in presence of sense oligonucleotide, xpressed as 
percent of control sample (control = 167 aortic SMCs or 120 graft SMCs per field). 
To verify that differences in migration were not 
caused by differences in proliferation, migration as- 
says were also performed after SMC incubation in 
antiproliferative agents. Quiescent SMCs were in- 
jured after a 2-hour incubation in 10 mM mitomycin 
C, or SMCs were incubated in 1 mM hydroxyurea for 
the 24 hours after injury. Migration assays revealed no 
difference in the number of cells migrating or distance 
travcled compared with untreated control samples. 
This verificd that proliferation was not a significant 
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Fig. 4. Effect of c-myb antisense on mean distance of SMC migration. Migration assay was 
performed as in Fig. 3, but distance of SMC migration at 24 hours was quantitated. A, Graft and 
aortic SMCs in presence of c-myb antisense, xpressed aspercentage ofcontrol samples. B, Graft 
and aortic SMCs in presence of sense oligonucleotide, expressed aspercentage ofcontrol samples. 
factor in this assay and that the effect of c-myb 
antisense on migration was not a result of its inhibi- 
tion of proliferation. 
To study the effect of the oligonucleotides on 
SMC viability, the growth of SMCs was arrested as 
described for studies of migration. No razor injury 
was performed after growth arrest; however, cells 
were placed in DMEM and FBS 0.5% with either 25 
gM sense or 25 gM antisense. Control wells con- 
tained no oligonucleotide. After 24 hours, cell viabil- 
ity was evaluated with trypan blue staining (Sigma), 
fluorescent DNA assay, and protein assay techniques. 
Nonviable cells that stained with trypan blue in 
control wells, 25 gM antisense wells, or 25 gM sense 
wells, represented 1.2%, 0.2%, and 0.2% of the total 
cells, respectively. No significant difference was found 
between oligonucleotide and control wells, which 
implies equivalent cell viability in all conditions after 
24 hours. Fluorescent DNA assay also suggested 
similar cell numbers between conditions. Control 
wells contained 102.2 + 7.3 pg DNA/well, whereas 
wells with 25 gM antisense contained 98.1 -+ 48.9 pg 
DNA/well (p = 0.87), and wells with 25 pM sense 
oligonucleotide contained 92.1 _+ 9.6 gg DNA/well 
(p = 0.17). Thus the DNA assay suggested no differ- 
ence in cell viability between control and experimen- 
tal conditions. Cell-associated protein synthesis was 
2.13 +0.16% of added [3H]leucine incorporated 
into TCA-precipitable material in control wells, 
1.67 _ 0.41% in 25 gM antisense wells (p = 0.06 to 
control samples), and 1.69 _+ 0.17% in 25 pM sense 
wells (p = 0.01 to control samples). Cell-secreted 
protein synthesis was 0.088% _+ 0.019% in control 
wells, 0.060% _+ 0.015% in 25 gM antisense wells 
(p = 0.07 to control wells), and 0.062% _ 0.001% in 
25 gM sense wells (p = 0.07 to control wells). These 
results demonstrate that cell-associated and cell- 
secreted protein was similar between antisense and 
sense groups but was slightly suppressed compared 
with untreated control cells. This may reflect a sup- 
pressive ffect ofphosphorothioate oligonucleotides 
on protein synthesis. Together, however, these vi- 
ability assays suggest hat SMC viability was not 
significantly altered by treatment with the highest 
concentrations of oligonucleotides used in this 
study. 
DISCUSSION 
Inhibition of SMC migration and proliferation 
could limit restenosis after balloon angioplasty and 
anastomotic IH in prosthetic grafts. Blocking anti- 
bodies directed against a specific mitogen partially 
inhibit IH; 1~a2 but an agent that blocks a common 
pathway shared by multiple mitogens may be more 
effective. The use of c-myb antisense to inhibit SMC 
proliferation in vitro and after arterial injury in vivo 
has been reported by several investigators. 14,1s,2~,22 
Initial reports of the efficacy of these compounds, 
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however, have been followed by studies that failed to 
show consistency in the growth-inhibiting effects of 
c-myb antiscnse.23 One possible xplanation for these 
discrepancies is a difference in the basal proliferation 
rate of SMCs from various ources. Previous tudies in 
our laboratory suggest differences in mitogen pro- 
duction by cells on prosthetic grafts compared with 
arteries s,9 and a higher initial proliferation rate of graft 
versus aortic SMCs in vitro, which raises a question as 
to the potential effectiveness of c-myb antisense in the 
reduction of graft SMC proliferation. Results of our 
current studies uggest only insignificant differences 
in inhibition of graft and aortic SMC proliferation. 
The similarity of the response of graft and aortic 
SMCs to c-myb antisense in vitro does not guarantee 
inhibition in vivo, but it does verify that these SMCs 
arc capable of being inhibited by c- myb antisensc. This 
finding suggests that c-myb antisense might be effec- 
tive in blocking both arterial and graft SMC prolif- 
eration in vivo despite the greater mitogen produc- 
tion by graft SMCs. 
In addition to proliferation, SMC migration plays 
a critical role in the development of IH after arterial 
injury or prosthetic vascular graft placement. Simons 
et al. 15 demonstrated that c-myb antisense inhibited 
IH after balloon injury of the rat carotid artery and 
interpreted this finding as implying that both prolif- 
eration and migration are inhibited. They did not, 
however, directly evaluate the effect of c-myb anti- 
sense on SMC migration. Our results demonstrate 
that c-myb antisense inhibits migration in a dose- 
dependent fashion, with similar degrees of inhibition 
in both arterial and graft SMCs. Both the number of 
cells migrating and the mean distance traveled are 
reduced, but the number of SMCs migrating was 
reduced to a greater degree than the distance traveled. 
This suggests hat either a subpopulation fcells is not 
affected by c- myb antisense or that once the signal to 
migrate is received, migration is not inhibited by 
antisense. 
The signal transduction pathways that control 
SMC proliferation and migration are not known in 
detail. A mitogenic stimulus results in early induction 
of c- myc and c-fosmRNA at 30 minutes to 2 hours and 
expression of c-myb at 8 to 12 hours. 24 The proto- 
oncogene myb encodes a DNA-binding protein that 
functions as an intracellular growth mediator. It is 
expressed at low levels in quiescent SMCs, increases 
rapidly as proliferation begins, peaks at 12 hours in the 
late G~ phase of the cell cycle, and remains elevated 
during the S phase. 2s'26 c-myb appears to regulate 
calcium influx during the G1/S interface of the cell 
cycle. 2I The .ability of antisense oligonucleotides to
c-myb to block SMC entry into S phase has been 
demonstrated, 26 but how c-myb antisense inhibits 
migration is not clear. Possibly the calcium influx 
required for cell movement is also regulated by c- myb 
and blocked by antisense. Interestingly, the degree of 
inhibition by c-myb antisense is similar for both 
proliferation and migration, which suggests that a 
similar mechanism ay be responsible for both ef- 
fects. This finding contrasts with those from studies of 
c-myc antisense in which SMC migration is inhibited 
by a lower concentration of antisense than prolifera- 
tion, 27 which suggests a different mechanism of 
action. 
Our studies did not address the mechanism of 
action of c-myb antisense. It is believed that antisense 
oligonucleotides hybridize with the corresponding 
mRNA and prevent i s transport out of the nucleus or 
translation into protein, or promote destruction of 
the mRNA by ribonucleases. These actions result in 
lower production of the relevant protein. Burgess et 
al. 28 and Villa et al.,23 however, recently suggested 
that the antiproliferative effect of c-myb antisense is
not caused by a hybridization-dependent mechanism, 
but by the presence of four contiguous guanosine 
residues in the oligonucleotide sequence that may 
bind to serum proteins. Simons and Rosenberg ~4 
demonstrated that c-myb antisense decreased c-myb 
mRNA and protein levels, but whether this was a 
primary effect or a result of diminished mitogcnic 
stimulation was not clear. Interestingly, Biro et al. 27 
demonstrated that some antisense sequences that 
contain four guanosine residues have no effect on 
SMC proliferation, which suggests that four contigu- 
ous guanosine residues is not sufficient o produce 
growth inhibition. Guvakova et al. 29 showed that 
phosphorothioate oligonucleotides bind bFGF, and 
this property may reduce SMC proliferation and 
migration. This did not play a significant role in our 
studies, however, as evidenced by lack of inhibition by 
the phosphorothioate s nse oligonucleotide. Thus 
the mechanism by which c-myb antisense inhibited 
proliferation or migration is not understood. 
SMC migration and proliferation contribute to 
the accumulation fSMC and the development ofIH 
after arterial injury or prosthetic vascular graft place- 
mcnt. Earlier studies have suggested that inhibition of 
SMC migration and proliferation for several days after 
rat arterial injury is sufficient to achieve a long-term 
reduction of IH. ~2,3° Whether the same is true in 
vascular grafts, where a sustained "injury" results 
from the presence of prosthetic material, is not 
known. Application of c-myb antisense inpluronic gel 
or an EVAc matrix to prolong delivery after arterial 
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injury inhibited c-myb mRNA expression and sup- 
pressed SMC accumulation) 5,22 These in vivo results, 
combined with our studies that demonstrate that 
aortic and graft SMC proliferation and migration are 
inhibited in a dose-dependent fashion by c-myb anti- 
sense in vitro, suggest hat c-myb antisense may be 
useful in the inhibition of IH at the anastomoses of
prosthetic grafts. If a sustained-release drug delivery 
system is used, c-myb antisense may limit SMC mi- 
gration and proliferation at the anastomosis and 
prolong graft patency. 
We gratefully acknowledge Meadox Medicals Inc., 
Oakland, N.J., for their donation of  6-mm internal diameter 
Cooley double-velour knitted Dacron grafts. 
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DISCUSSION 
Dr. J. Jeffrey Alexander (Cleveland, Ohio). The ex- 
pression of a variety of proto-oncogenes in response to the 
mitogenic stimulation of SMCs appears to play an impor- 
tant role in cell replication and possibly also in migration, 
and it may be linked to the development of IH. The 
blockade of effective gene transcription with specific anti- 
sense oligonucleotides has the potential to selectively in- 
hibit the production of intracellular growth mediators and 
would seem to have possible a clinical application in the 
suppression ofIH, assuming that an appropriate method of 
delivery could be developed. I would like to ask several 
questions of the authors regarding the methods and inter- 
pretation of their study results. In their previous work, the 
group from the Cleveland VA Hospital demonstrated an 
increase in mitogen production by graft SMCs. The current 
study shows no difference in the inhibition of autocrine 
stimulated SMC replication between graft and native cells in 
response to the antisense nucleotide. 
In fact, there appears to be somewhat greater inhibition 
of the native SMC replication. This is contrary to what we 
would expect o see because c-myb is normally activated by 
such mitogens. Burges and colleagues at the Amgen Cor- 
poration have recently reported that antisense oligonucle- 
otides penetrate plasma membrane ofnoninjured cells very 
poorly. In fact, most previous tudies that looked at this 
technique have used balloon injury models. These results 
suggest hat the inhibitory effect of the antisense may 
actually be extracytoplasmic and not sequence-specific. The 
demonstration f rapid reversibility may be consistent with 
this alternative mechanism of action. Was c-myb mRNA ever 
measured in your experiments o prove the true action of 
the antisense oligonucleotide? 
Second, in the real world, cell replication is likely to be 
stimulated by a variety of mitogens, leading to either the 
simultaneous or contiguous induction of several proto- 
oncogenes. Does the selective blockade of c-myb influence 
those others, and can use of a specific antisense oligonucle- 
otide be expected to alter the hyperplastic response in vivo? 
At the same time, do you believe that cell-cycle manipula- 
tion by the alteration of serum concentrations in your 
culture media is truly equivalent to the mitogenic stimula- 
tion associated with either cell injury or other forms of cell 
activation? 
Last, what was the role of endothelial cell seeding in this 
study? Seeding may introduce aconfounding factor. As you 
know, the presence of endothelial cells, the heparin that was 
used, and your methods of cell harvesting from both the 
native aorta and the graft may have affected the expression 
of c- myb. 
Dr. Robert  J. Htsch. We did not measure c-myb 
mRNA levels in this study, but they were measured by 
Simons and Rosenberg 14who used c-myb antisense to 
inhibit SMC proliferation. Antisense reduced the level of 
both c-myb mRNA and protein. We are measuring c-myb 
mRNA and protein levels in ongoing studies. 
It is always hazardous to extrapolate in vitro results to 
the in vivo setting. Serum contains multiple mitogens and is 
a potent stimulus for SMC proliferation. There are, how- 
ever, additional factors which may stimulate proliferation i
vivo. The demonstration byother investigators that c-myb 
antisense inhibits SMC proliferation after arterial injury, 
suggests that c-myb antisense blocks an essential pathway 
between receptor activation and cell division. These in vivo 
results also suggest hat c-myb antisense may block SMC 
accumulation on grafts. We have initiated studies on the 
effect of c-myb antisense on intimal hyperplasia in grafts 
implanted in dogs; however, these studies are at a very 
preliminary stage. 
Endothelial cell seeding of grafts was used to encourage 
the rapid development of a neointima composed of both 
endothelial cells and SMCs. Previous tudies in our labora- 
tory suggested that SMCs from the mid portion of endo- 
thelial cell seeded grafts behaved similarly to those from the 
anastomoses of control grafts with respect to proliferation 
and production of mitogens. Therefore, this model pro- 
vided a source of sufficient numbers of SMCs to perform 
experiments on early passage cells. 
Dr. David Brenin (Chicago, Ill.). Laying the ground- 
work that will allow the application of gene therapy to 
vascular surgery problems is important. Unfortunately, 
using an antisense mRNA in vivo will be difficult because of 
the extremely short half-life of mRNA. Have you investi- 
gated the transfer of genes for the antisense message using 
lipofection or a viral vector? 
Dr. Robert  J. Pitsch. We have not used any gene 
transfer methods in our studies of c-myb antisense. Devel- 
opment of appropriate antisense delivery systems will be 
necessary tomake this technology clinically useful, and gene 
transfer has the potential to provide chronic production of 
antisense oligonucleotides. Other delivery systems for an- 
tisense oligonucleotides, including the use of polymers for 
sustained local drug release, are currently being investi- 
gated. 
